Morphological variants of leukemic cells in B chronic lymphocytic leukemia are associated with different T cell and NK cell abnormalities

Reyes, Eduardo; Prieto, Alfredo; Carrión, F; García‐Suárez, Julio; Esquivel, F.; Álvarez‐Mon, Melchor

doi:10.1002/(sici)1096-8652(199707)55:4<175::aid-ajh2>3.0.co;2-p

Cited by 11 publications

(7 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The total numbers of T, NK and normal B cells at baseline were significantly higher in patients than in healthy donors. This is in accordance with previous observations in untreated B-CLL patients, 17,18 verifying the representativeness of our patient material and the robustness of our flow cytometry method. A profound reduction in all lymphoid subsets was observed.…”

Section: Discussionsupporting

confidence: 93%

Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia

et al. 2004

View full text Add to dashboard Cite

Little information is available on long-term immune reconstitution after therapy with alemtuzumab in B-CLL patients. We present long-term follow-up data for blood lymphocyte subsets analysed by flow cytometry in previously untreated B-CLL patients who received alemtuzumab subcutaneously as firstline therapy. All lymphoid subsets were significantly (Po0.001) and profoundly reduced; the median end-of-treatment counts þ and CD8 þ levels in blood had reached 4100 cells/ll in 450% of the patients at 4 months after the end of treatment. One patient had a cytomegalovirus reactivation and one patient developed Pneumocystis carinii pneumonia during therapy. No opportunistic or other major infections were recorded during unmaintained, long-term follow-up. There was no correlation between the cumulative dose of alemtuzumab and the severity or length of immunosuppression. CD52À T-cell subsets occurred during the treatment and comprised 480% of all CD4 þ and CD8 þ cells in the blood at the end of therapy. These subpopulations declined gradually during unmaintained followup. The relationship between these observations and the safety/antitumour effects of alemtuzumab is discussed.

show abstract

Section: Discussionsupporting

confidence: 93%

Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia

et al. 2004

View full text Add to dashboard Cite

show abstract

“…A higher proportion of IL‐4 and IFN‐γ producing T cells has been reported in B‐CLL patients compared to normal controls (19, 20). A varying pattern of IL‐4 and IL‐2 producing T cells was noted in patients with B‐CLL of different morphologies (25). In patients with smouldering disease a low secretion of IFN‐γ and IL‐4 was noted as compared to patients with non‐smouldering leukaemia (18).…”

Section: Discussionmentioning

confidence: 99%

Intracellular T cell cytokines in patients with B cell chronic lymphocytic leukaemia (B‐CLL)

Rossmann

Lewin

Jeddi‐Tehrani

et al. 2002

European J of Haematology

View full text Add to dashboard Cite

Analysis of cytokine production is a tool to functionally characterise T cells. In this study, spontaneous and polyclonal activation induced cytokine production in T cells were assessed by flow cytometry in patients with B-CLL. Patients with progressive disease had a significantly increased number of T cells spontaneously producing IL-2, IL-4 and GM-CSF as compared to healthy donors and patients with non-progressive CLL, which was not the case for TNF-alpha and IFN-gamma producing T cells. However, no difference in the frequency of T cells producing these cytokines was seen comparing patients with non-progressive disease to control donors. Polyclonal activation of B-CLL T cells in vitro induced an increased proportion of T cells producing these five cytokines in patients as well as in control donors, indicating that T cells in CLL patients might have a relatively well preserved functional capacity. However, the increase in GM-CSF, TNF-alpha and IL-4 producing T cells was more marked in CLL patients than in controls. Furthermore, following activation, a higher frequency of cytokine-producing T cells was noted in patients with progressive disease as compared to those with non-progressive disease. The augmented number of cytokine-producing T cells in CLL may indicate an up-regulated capability of T cells to secrete cytokines, especially in patients with progressive CLL. The increased production of the T cell derived cytokines GM-CSF, TNF-alpha, IL-4 and IL-2 is interesting, as these cytokines have previously been shown to support growth of B-CLL leukaemic cells in vitro and as T cells might specifically recognise the autologous leukaemic B cells in vivo. The findings may suggest a role for T cells in the pathogenesis of B-CLL.

show abstract

“…ZAP‐70 overexpression was associated with redistribution of the CD4 T lymphocyte compartment, characterized by a collapse of naïve cells and selective expansion of NTEM and TEM cells. These findings allow understanding of previous contradictory reports on the distribution of naïve and memory CD4 subsets defined by expression of CD45 isoforms in B‐CLL patients .…”

Section: Discussionmentioning

confidence: 52%

“…Various abnormalities have been described in the T cell compartment, including redistribution of cell subsets such as those defined by expression of the CD4 and CD8 antigens and the RO and RA isoforms of CD45 . T cell alterations also include anomalous gene expression, restricted T cell receptor V gene usage, an impaired CD3 activation transduction system, the proliferative response to mitogens, and up‐ or downregulation of co‐receptor and surface molecules . Finally, CD8 T lymphocytes from B‐CLL patients show defective lytic activity in effector cytotoxicity and alterations in cytokine production .…”

mentioning

confidence: 99%

Distinctive patterns of naïve/memory subset distribution and cytokine expression in CD4 T lymphocytes in ZAP-70 B-chronic lymphocytic patients

et al. 2013

View full text Add to dashboard Cite

show abstract

Morphological variants of leukemic cells in B chronic lymphocytic leukemia are associated with different T cell and NK cell abnormalities

Abstract: B chronic lymphocytic leukemia (B-CLL

Cited by 11 publications

References 3 publications

Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia

Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia

Intracellular T cell cytokines in patients with B cell chronic lymphocytic leukaemia (B‐CLL)

Distinctive patterns of naïve/memory subset distribution and cytokine expression in CD4 T lymphocytes in ZAP-70 B-chronic lymphocytic patients

Contact Info

Product

Resources

About